ImmunoPrecise Antibodies Gross Profit

ImmunoPrecise Antibodies (IPA) currently reports a gross profit of $11M as of January 2026. That compares with $12M in the prior-year period — down 9.0% year over year. That is below the Healthcare sector average of $65B. Use the charts on this page to explore ImmunoPrecise Antibodies's gross profit history and peer comparisons.

ImmunoPrecise Antibodies's gross profit decreased from $12M to $11M — a 9.0% year-over-year decrease (period ending January 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ImmunoPrecise Antibodies's gross profit of $11M is lower than the Healthcare sector average of $65B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

ImmunoPrecise Antibodies reported $11M in gross profit as of January 2026. That compares with $12M in the prior-year period — down 9.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $65B. From there, open related valuation or income-statement pages for ImmunoPrecise Antibodies, and consider following IPA for alerts when major investors trade the stock.